Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among US adults

被引:97
作者
Hyre, Amanda D.
Muntner, Paul
Menke, Andy
Raggi, Paolo
He, Jiang
机构
[1] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA
[2] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
[3] Emory Univ, Sch Med, Dept Med Radiol, Atlanta, GA USA
关键词
lipoproteins; LDL cholesterol; guidelines; NHANES;
D O I
10.1016/j.annepidem.2007.01.032
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: We sought to determine trends in the prevalence, awareness, treatment and control of high low-density lipoprotein (LDL) cholesterol among U.S. adults. METHODS: Data from 6497 participants of the Third National Health and Nutrition Examination Survey (NHANES) conducted in 1988-1994 and 5626 participants of NHANES 1999-2004 were compared. High LDL cholesterol was defined using risk-specific cut-points from the National Cholesterol Education Program's Adult Treatment Panel III guidelines. RESULTS: The age -standardized percentage of U.S. adults with high LDL cholesterol was 26.6% in 1988-1994 and 25.3% in 1999-2004 (P = 0.28). Between 1988-1994 and 1999-2004, awareness increased from 39.2% to 63.0%, and use of pharmacologic lipid-lowering treatment increased from 11.7% to 40.8% (each p < 0.001). LDL cholesterol control increased from 4.0% to 25.1% among those with high LDL cholesterol (p < 0.001). In 1999-2004, rates of LDL cholesterol control were lower among adults ages 20-49 years compared with those age 65 years or older (13.9% vs. 30.3%; p < 0.001); non-Hispanic blacks and Mexican-Americans compared with non-Hispanic whites (17.2% and 16.5% vs. 26.9%, respectively; p = 0.05 and p = 0.008); and males compared with females (22.6% vs. 28.0%; p = 0.01). CONCLUSIONS: Continued efforts are needed to lower the burden of high LDL cholesterol and increase LDL cholesterol control, especially among populations with low control rates.
引用
收藏
页码:548 / 555
页数:8
相关论文
共 20 条
[1]  
[Anonymous], 2002, JAMA
[2]   Discovering the full spectrum of cardiovascular disease - Minority health summit 2003 - Report of the outcomes writing group [J].
Benjamin, EJ ;
Jessup, M ;
Flack, JM ;
Krumholz, HM ;
Liu, K ;
Nadkarni, VM ;
Rhoades, DA ;
Rodriguez, BL ;
Scott, RP ;
Taylor, MP ;
Velazquez, EJ ;
Winkleby, MA .
CIRCULATION, 2005, 111 (10) :E124-E133
[3]   New advances in lipid-modifying therapies for reducing cardiovascular risk [J].
Bruckert, E .
CARDIOLOGY, 2002, 97 (02) :59-66
[4]   Trends in serum lipids and lipoproteins of adults, 1960-2002 [J].
Carroll, MD ;
Lacher, DA ;
Sorlie, PD ;
Cleeman, JI ;
Gordon, DJ ;
Wolz, M ;
Grundy, SM ;
Johnson, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14) :1773-1781
[5]  
*CDCP, 2001, NAT CANC HLTH STAT N
[6]  
*CDCP, 2002, NAT CANC HLTH STAT N
[7]  
*CDCP, 1992, NAT CANC HLTH STAT N
[8]  
Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P117
[9]  
CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497